John Yonchuk
YOU?
Author Swipe
View article: Development of Respercise® a Digital Application for Standardizing Home Exercise in COPD Clinical Trials
Development of Respercise® a Digital Application for Standardizing Home Exercise in COPD Clinical Trials Open
Respercise can be successfully deployed in clinical trials, offering the opportunity for standardization of exercise in clinical trials and, with further development, could have wider reach as a home-based intervention for individuals with…
View article: Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Biomarker of COPD 
Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Biomarker of COPD Open
Background:Soluble receptor for advanced glycation end products (sRAGE) is a proposed emphysema and airflow obstruction biomarker; however, previous publication have shown inconsistent associations and only one study has investigate the as…
View article: 3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent
3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent Open
IκB kinase β (IKKβ or IKK2) is a key regulator of nuclear factor kappa B (NF-κB) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activ…
View article: Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD
Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD Open
Approximately one-third of patients with chronic obstructive pulmonary disease (COPD) have chronic mucus hypersecretion (CMH) [1], often referred to as chronic bronchitis. Despite treatment with inhaled medications and other therapies, suc…
View article: Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2
Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2 Open
CXC chemokine receptor 2 (CXCR2) is a key receptor in the chemotaxis of neutrophils to sites of inflammation. The studies reported here describe the pharmacological characterization of danirixin, a CXCR2 antagonist in the diaryl urea chemi…
View article: Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery
Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery Open
KEAP1 is the key regulator of the NRF2-mediated cytoprotective response, and increasingly recognized as a target for diseases involving oxidative stress. Pharmacological intervention has focused on molecules that decrease NRF2-ubiquitinati…